New Haven’s Kolltan Pharmaceuticals said it’s raised $60 million from investors as it prepares to head into clinical trials for its cancer therapy.
Kolltan’s monoclonal antibody technology was created at Yale University.
The company raised the money from 34 investors starting March 13.
A spokesman for the company declined on Thursday afternoon to offer details about how the company would use the money.
